A Phase 4 interventional study of Ceftriaxone and Ampicillin/sulbactam in Open Fracture and Post-Op Wound Infection, sponsored by Mercy Health Ohio. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-11.
Sponsored by Mercy Health Ohio · Phase 4, Interventional, and Prevention
To demonstrate noninferiority of three different empiric antimicrobial regimens compared to the traditional antimicrobial regimen for the management of grade III open fractures as well as evaluate outcomes among these groups.
Per the EAST practice management guidelines, an open fracture is defined as one in which the fracture fragments communicate with the environment through a break in the skin. The presence of an open fracture, either isolated or as part of a multiple injury complex, increases the risk of infection and soft tissue complications. Open fractures are further classified into Grade I - Grade III fractures per the Gustilo Classification. Grade III fractures are those with the highest likelihood of contamination and infection with infection rates ranging from 10% to 42%.
EAST guidelines currently recommend systemic gram positive coverage for all open fractures with the addition of gram negative coverage for all Grade III fractures. Antibiotics should be initiated as soon as possible following the injury and should be continued for 72 hours after the injury or not greater than 24 hours after soft tissue coverage was obtained. Traditionally, patients received the combination of Cefazolin and Gentamicin as the preferred prophylactic antibiotic regimen, despite the need for multiple antibiotics and the risk of nephrotoxicity associated with aminoglycosides. Whether there is clinically a more ideal prophylactic antibiotic available remains to be seen. This proposed research initiative is intended to evaluate several antibiotic regimens with similar spectrums of activity to see if there is an equally effective single agent with minimal nephrotoxicity associated with its use. In selecting the study antibiotics to be utilized in the protocol, available information was obtained regarding timing of antibiotics, organisms identified by culture results, and any studies available on specific antibiotic regimens. In regards to timing, there is evidence to support that time to antibiotics and time to the operating room may be more important than the particular antibiotic itself. Additionally, a recent study from 2015 looked at the organisms identified from culture results for Grade I through Grade III fractures in Germany. The vast majority of cultures obtained were gram positive organisms, even in the Grade III fractures, and included Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus capitis, various Streptococcus species, Enterococcus faecium and Corynebacterium. Interestingly, the only gram negative organism identified in the study was Escherichia coli. Lastly, when trying to identify antibiotic specific studies, a recent study was identified looking at Ceftriaxone as the agent of choice, while limiting the use of vancomycin and aminoglycosides. The conclusion of the study showed a significant decrease in vancomycin and aminoglycosides administered with no increase in infection rates.
Here at St. Elizabeth Youngstown Hospital, the investigator's current trauma and orthopedics practice management guideline has been reviewed and changed multiple times in the past several years. For the vast majority of time, the recommendation has been to use the traditional cefazolin/gentamicin combination. However, several cases of nephrotoxicity led to some hesitation in utilizing this regimen. Therefore, for a short time period, piperacillin/tazobactam was being used for all Grade III fractures instead. At present however, due to conflicting concerns regarding antimicrobial stewardship with utilizing broad spectrum piperacillin/tazobactam with the nephrotoxicity concerns of gentamicin, the approved guideline utilizes cefazolin/gentamicin for patients under 65 years of age and piperacillin/tazobactam for all patients greater than or equal to 65 years of age. This study aims to evaluate non-inferiority of ampicillin/sulbactam, ceftriaxone, and piperacillin/tazobactam when compared to the traditional regimen of cefazolin/gentamicin for grade III open fractures.
53 studies on the registry are indexed under Fractures, Open; 14 are open to participants now.
This study's enrollment of 17 is below the median of 90 across 40 interventional studies indexed under Fractures, Open.
Browse Fractures, Open studies →Mercy Health Ohio is the lead sponsor of 15 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
\[Cefazolin\] Initial dose: * Cefazolin 2g IV x1 dose (patient weight \< 120kg) * Cefazolin 3g IV x1 dose (patient weight \>/= 120kg) Subsequent dose: * Cefazolin 2g IV every 8 hrs (CrCl \>/= 40 mL/min) * Cefazolin 2g IV every 12 hrs (CrCl 20-39 mL/min) * Cefazolin 2g IV every 24 hrs (CrCl \< 20 mL/min) Duration: * 24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first \[Gentamicin\] Initial dose: * If Patient age \</= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg) * If Patient age \>80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg) Subsequent dose: * Pharmacy Consult to dose gentamicin Duration: * 24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first
Drug: Cefazolin + Gentamicin
Initial dose: * Ceftriaxone 2g IV x1 dose Subsequent dose: * Ceftriaxone 2g IV every 24 hours Duration: * One dose post-op after soft tissue coverage or total of 72 hours, whichever comes first
Drug: Ceftriaxone
Initial dose: * Ampicillin/Sulbactam 3g IV x1 dose Subsequent dose: * Ampicillin/Sulbactam 3g IV every 6 hours (CrCl \>/= 30 mL/min) * Ampicillin/Sulbactam 3g IV every 12 hours (CrCl 15-29 mL/min) * Ampicillin/Sulbactam 3g IV every 24 hours (CrCl \<15 mL/min) Duration: * 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first
Drug: Ampicillin/sulbactam
Initial dose: * Piperacillin/Tazobactam 4.5g IV x1 dose over 30 minutes Subsequent dose: * Piperacillin/Tazobactam 3.375g IV every 8 hours over 4 hours (CrCl \>/= 20 mL/min) * Piperacillin/Tazobactam 3.375g IV every 12 hours over 4 hours (CrCl \< 20 mL/min) Duration: * 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first
Drug: Piperacillin/tazobactam
Patients with known Penicillin allergy will receive: \[Clindamycin\] Initial dose: * Clindamycin 900mg IV x1 dose Subsequent dose: * Clindamycin 600mg IV every 8 hours Duration: * 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first \[Gentamicin\] Initial dose: * If Patient age \</= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg) * If Patient age \>80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg) Subsequent dose: * Pharmacy Consult to dose gentamicin Duration: * 24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first
Drug: Clindamycin + Gentamicin
See arm description
Also known as: Rocephin
Drug pages: Ampicillin · Sulbactam
See arm description
Also known as: Unasyn
See arm description
Also known as: Zosyn
Drug pages: Cefazolin · Gentamicins
See arm description
Also known as: Ancef + Garamycin
Drug pages: Clindamycin · Gentamicins
See arm description
Also known as: Cleocin + Garamycin
Post-surgical site wound infections
The primary outcome for this study is the number of post-surgical site wound infections, defined as initiation of antibiotics for surgical-site infection and/or need for surgical debridement of site. The acceptable infection rate per Trauma Practice Management Guidelines states a rate less than 20%.
Time frame: 1 year
Incidence of acute kidney injury
Incidence of acute kidney injury during hospital admission will be collected and compared to the other antibiotic regimens. Acute kidney injury is defined as (per KDIGO guidelines): * An increase in SCr by 0.3 mg/dL within 48 hours OR * Increase in SCr to 1.5 times baseline within the previous 7 days OR * Urine volume less than 0.5 mL/kg/h for 6 hours
Time frame: Hospital admission
Average cost of antibiotic therapy per patient
Cost per patient of each antibiotic therapy will be calculated and compared to the other antibiotic regimens
Time frame: Hospital admission
Time to antibiotic therapy
Time from arrival to receiving first dose of antibiotic therapy will be collected (Goal within 30 minutes of arrival).
Time frame: Hospital admission
Plan to share: No
This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ceftriaxone · Ampicillin · Sulbactam · Cefazolin · Gentamicins · Clindamycin
Mercy Health Ohio